glucophage xr 750 mg
merck serono ltd - metformin hydrochloride - tablets prolonged release - metformin hydrochloride 750 mg - metformin - • reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with igt* and/or ifg*, and/or increased hba1c who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 monthstreatment with glucophage xr must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.*igt: impaired glucose tolerance; ifg: impaired fasting glucose• treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. glucophage xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
glucophage 500mg tablet
merck sdn. bhd. - metformin hydrochloride -
glucophage 850mg tablet
merck sdn. bhd. - metformin hydrochloride -
glucophage-dr tablets
rona laboratories limited - metformin hydrochloride - tablets
glucophage-xr 750mg tablet, extended release
merck inc - metformin hydrochloride - tablet, extended release - 750mg
glucophage tablets (pom)
metformin 500mg
glucophage tablets (pom)
metformin hydrochloride 500mg
glucophage
viatris limited - metformin hydrochloride 500mg; - film coated tablet - 500 mg - active: metformin hydrochloride 500mg excipient: hypromellose magnesium stearate povidone
glucophage
viatris limited - metformin hydrochloride 850mg; - film coated tablet - 850 mg - active: metformin hydrochloride 850mg excipient: hypromellose magnesium stearate povidone
glucophage caplets (pom)
metformin 1000mg